🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Efficacy and Safety of the APGO Algorithm for Automated Insulin Delivery

RecruitingNAAges 18 Years - anyAllCharles University, Czech Republic
NCT07320495 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The Medtrum TouchCare Nano system with the APGO algorithm is the only patch pump-based automated insulin delivery system available in the Czech Republic. However, until now, no prospective clinical study has evaluated its efficacy and safety under real-world conditions. The RENEW study is the first to address this topic.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * patients with T1D * type 1 diabetes for ≥1 years * ≥ 18 years old * written informed consent prior to starting study related activity Exclusion Criteria: * severe noncompliance * lactation, pregnancy, intending to become pregnant during study * use of medication with effects on carbohydrate metabolism
💊

What it tests

  • Device: Insulin pump TouchCare Nano A8 with the APGO system
📍

Where

1 site
3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czechia
Prague, Czechia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy